BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:BIO.B • US0905721082
295.05 USD
-17.7 (-5.66%)
Last: Feb 2, 2026, 08:04 PM
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While BIO.B has a great health rating, its profitability is only average at the moment. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year BIO.B was profitable.
- In the past year BIO.B had a positive cash flow from operations.
- In multiple years BIO.B reported negative net income over the last 5 years.
- Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
- BIO.B has a Return On Assets (-6.97%) which is in line with its industry peers.
- BIO.B has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
- Looking at the Return On Invested Capital, with a value of 2.26%, BIO.B is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO.B has a Operating Margin of 10.27%. This is in the better half of the industry: BIO.B outperforms 68.97% of its industry peers.
- BIO.B's Operating Margin has been stable in the last couple of years.
- With a decent Gross Margin value of 52.42%, BIO.B is doing good in the industry, outperforming 62.07% of the companies in the same industry.
- In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, BIO.B has less shares outstanding
- The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
- BIO.B has a worse debt/assets ratio than last year.
2.2 Solvency
- BIO.B has an Altman-Z score of 3.43. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
- BIO.B's Altman-Z score of 3.43 is fine compared to the rest of the industry. BIO.B outperforms 68.97% of its industry peers.
- BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
- BIO.B's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO.B outperforms 75.86% of its industry peers.
- BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- BIO.B's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO.B outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.43 |
ROIC/WACC0.21
WACC10.74%
2.3 Liquidity
- A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
- BIO.B's Current ratio of 5.44 is amongst the best of the industry. BIO.B outperforms 84.48% of its industry peers.
- A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
- BIO.B's Quick ratio of 3.94 is fine compared to the rest of the industry. BIO.B outperforms 67.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.90%.
- BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
- BIO.B shows a decrease in Revenue. In the last year, the revenue decreased by -0.88%.
- Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- Based on estimates for the next years, BIO.B will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 28.62, BIO.B can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 68.97% of the companies listed in the same industry.
- BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.92, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 28.78, which means the current valuation is very expensive for BIO.B.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 63.79% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.78, BIO.B is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.62 | ||
| Fwd PE | 28.78 |
4.2 Price Multiples
- BIO.B's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 77.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.63 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.65
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
5. Dividend
5.1 Amount
- BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO.B (2/2/2026, 8:04:00 PM)
295.05
-17.7 (-5.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners92.92%
Inst Owner Change0.28%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap7.96B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (23.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)-1.58%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-3.02%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)4.13%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.62 | ||
| Fwd PE | 28.78 | ||
| P/S | 3.11 | ||
| P/FCF | 23.63 | ||
| P/OCF | 16.19 | ||
| P/B | 1.18 | ||
| P/tB | 1.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.49%
EPS(NY)10.25
Fwd EY3.47%
FCF(TTM)12.48
FCFY4.23%
OCF(TTM)18.22
OCFY6.18%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.65
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.43 |
F-Score5
WACC10.74%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.